Trademark: 88787581
Status Date
Monday, May 29, 2023
Filing Date
Thursday, February 6, 2020
Published for Opposition
Tuesday, November 3, 2020
Abandoned Date
Monday, May 29, 2023
5 therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor; therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19
44 providing a website featuring information in the field of antibodies for use in targeting the CCR5 cell receptor; providing health and medical information, namely, providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19
42 scientific research consulting services in the field of immunology; scientific research consulting services in the field of antibodies for use in targeting the CCR5 cell receptor; scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services; medical research and medical analysis services in the field of antibodies for use in targeting the CCR5 cell receptor; medical research and analysis services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19
May 30, 2023
Abandonment Notice E-Mailed - No Use Statement Filed
May 29, 2023
Abandonment - No Use Statement Filed
Oct 29, 2022
Notice Of Approval Of Extension Request E-Mailed
Oct 27, 2022
Sou Extension 3 Granted
Oct 27, 2022
Sou Extension 3 Filed
Oct 27, 2022
Sou Teas Extension Received
Apr 29, 2022
Notice Of Approval Of Extension Request E-Mailed
Apr 27, 2022
Sou Extension 2 Granted
Apr 27, 2022
Sou Extension 2 Filed
Apr 27, 2022
Sou Teas Extension Received
Oct 27, 2021
Notice Of Approval Of Extension Request E-Mailed
Oct 25, 2021
Sou Extension 1 Granted
Oct 25, 2021
Sou Extension 1 Filed
Oct 25, 2021
Sou Teas Extension Received
Apr 27, 2021
Noa E-Mailed - Sou Required From Applicant
Mar 14, 2021
Extension Of Time To Oppose Process - Terminated
Dec 1, 2020
Extension Of Time To Oppose Received
Nov 3, 2020
Official Gazette Publication Confirmation E-Mailed
Nov 3, 2020
Published For Opposition
Oct 14, 2020
Notification Of Notice Of Publication E-Mailed
Sep 29, 2020
Approved For Pub - Principal Register
Sep 29, 2020
Teas/Email Correspondence Entered
Sep 28, 2020
Correspondence Received In Law Office
Sep 28, 2020
Teas Response To Office Action Received
Mar 28, 2020
Notification Of Non-Final Action E-Mailed
Mar 28, 2020
Non-Final Action E-Mailed
Mar 28, 2020
Non-Final Action Written
Mar 28, 2020
Notification Of Non-Final Action E-Mailed
Mar 28, 2020
Non-Final Action E-Mailed
Mar 28, 2020
Non-Final Action Written
Mar 26, 2020
Assigned To Examiner
Feb 10, 2020
New Application Office Supplied Data Entered
Feb 10, 2020
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
